Galera Therapeutics (GRTX) Competitors

$0.10 0.00 (0.00%)

As of 05/26/2026 03:27 PM Eastern

GRTX vs. SCYX, MYNZ, LSTA, QNTM, and BGM

Should you buy Galera Therapeutics stock or one of its competitors? MarketBeat compares Galera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galera Therapeutics include SCYNEXIS (SCYX), Mainz Biomed (MYNZ), Lisata Therapeutics (LSTA), Quantum Biopharma (QNTM), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry.

How does Galera Therapeutics compare to SCYNEXIS?

Galera Therapeutics (NASDAQ:GRTX) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Galera Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Galera Therapeutics' return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Galera Therapeutics has a beta of 2.64, meaning that its share price is 164% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

In the previous week, SCYNEXIS had 3 more articles in the media than Galera Therapeutics. MarketBeat recorded 3 mentions for SCYNEXIS and 0 mentions for Galera Therapeutics. Galera Therapeutics' average media sentiment score of 0.00 beat SCYNEXIS's score of -0.44 indicating that Galera Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Galera Therapeutics	Neutral
SCYNEXIS	Neutral

50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 4.9% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

SCYNEXIS has a consensus price target of $3.00, suggesting a potential upside of 320.76%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Galera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SCYNEXIS has higher revenue and earnings than Galera Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.16
SCYNEXIS	$20.60M	1.55	-$8.61M	-$0.48	N/A

Summary

SCYNEXIS beats Galera Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Galera Therapeutics compare to Mainz Biomed?

Galera Therapeutics (NASDAQ:GRTX) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Galera Therapeutics has a beta of 2.64, suggesting that its share price is 164% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Mainz Biomed has higher revenue and earnings than Galera Therapeutics. Mainz Biomed is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.16
Mainz Biomed	$659.94K	47.64	-$21.65M	-$65.60	N/A

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
Mainz Biomed	N/A	N/A	N/A

50.8% of Galera Therapeutics shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled Mainz Biomed'saverage media sentiment score.

Company	Overall Sentiment
Galera Therapeutics	Neutral
Mainz Biomed	Neutral

Summary

Mainz Biomed beats Galera Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Galera Therapeutics compare to Lisata Therapeutics?

Galera Therapeutics (NASDAQ:GRTX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Galera Therapeutics' return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
Lisata Therapeutics	N/A	-103.54%	-83.08%

In the previous week, Lisata Therapeutics' average media sentiment score of 2.00 beat Galera Therapeutics' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Galera Therapeutics	Neutral
Lisata Therapeutics	Very Positive

Lisata Therapeutics has higher revenue and earnings than Galera Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.16
Lisata Therapeutics	$170K	173.41	-$16.59M	-$1.86	N/A

Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 363.54%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than Galera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Galera Therapeutics has a beta of 2.64, indicating that its share price is 164% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Summary

Galera Therapeutics and Lisata Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Galera Therapeutics compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Galera Therapeutics' return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Galera Therapeutics	N/A	N/A	-99.34%

In the previous week, Quantum Biopharma had 1 more articles in the media than Galera Therapeutics. MarketBeat recorded 1 mentions for Quantum Biopharma and 0 mentions for Galera Therapeutics. Quantum Biopharma's average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Galera Therapeutics	Neutral

Quantum Biopharma is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.16

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Quantum Biopharma has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Galera Therapeutics has a beta of 2.64, suggesting that its stock price is 164% more volatile than the broader market.

Summary

Galera Therapeutics beats Quantum Biopharma on 7 of the 10 factors compared between the two stocks.

How does Galera Therapeutics compare to BGM Group?

BGM Group (NASDAQ:BGM) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Galera Therapeutics	N/A	N/A	-99.34%

In the previous week, BGM Group's average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score.

Company	Overall Sentiment
BGM Group	Neutral
Galera Therapeutics	Neutral

50.8% of Galera Therapeutics shares are held by institutional investors. 58.7% of BGM Group shares are held by company insiders. Comparatively, 12.9% of Galera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BGM Group has higher revenue and earnings than Galera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$26.85M	1.17	-$1.44M	N/A	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.16

BGM Group has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Galera Therapeutics has a beta of 2.64, indicating that its stock price is 164% more volatile than the broader market.

Summary

BGM Group beats Galera Therapeutics on 5 of the 7 factors compared between the two stocks.

Get Galera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRTX vs. The Competition

Export

Metric	Galera Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.55M	$941.26M	$6.39B	$12.47B
Dividend Yield	N/A	4.84%	2.76%	5.27%
P/E Ratio	-0.29	1.44	20.84	25.88
Price / Sales	N/A	135.10	514.47	69.69
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	-0.04	7.73	10.44	7.15
Net Income	-$59.08M	-$3.91M	$3.57B	$337.22M
7 Day Performance	N/A	3.26%	3.02%	3.40%
1 Month Performance	N/A	76.55%	2.47%	3.51%
1 Year Performance	N/A	125.57%	36.43%	36.52%

Galera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRTX Galera Therapeutics	N/A	$0.10 flat	N/A	+311.5%	$7.55M	N/A	N/A	30	Gap Up
SCYX SCYNEXIS	1.9153 of 5 stars	$0.67 +0.5%	$3.00 +347.1%	-12.2%	$29.97M	$20.60M	N/A	60	Stock Split
MYNZ Mainz Biomed	N/A	$3.29 +30.6%	N/A	+58.6%	$29.81M	$659.94K	N/A	30	High Trading Volume
LSTA Lisata Therapeutics	2.2665 of 5 stars	$3.24 +1.9%	$15.00 +363.1%	+21.2%	$29.51M	$170K	N/A	30	Positive News
QNTM Quantum Biopharma	0.1447 of 5 stars	$7.72 -1.2%	N/A	-39.0%	$29.48M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRTX) was last updated on 5/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galera Therapeutics (GRTX) Competitors

GRTX vs. SCYX, MYNZ, LSTA, QNTM, and BGM

How does Galera Therapeutics compare to SCYNEXIS?

Summary

How does Galera Therapeutics compare to Mainz Biomed?

Summary

How does Galera Therapeutics compare to Lisata Therapeutics?

Summary

How does Galera Therapeutics compare to Quantum Biopharma?

Summary

How does Galera Therapeutics compare to BGM Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRTX vs. The Competition

Galera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galera Therapeutics (GRTX) Competitors

GRTX vs. SCYX, MYNZ, LSTA, QNTM, and BGM

How does Galera Therapeutics compare to SCYNEXIS?

Is GRTX or SCYX more profitable?

Which has more volatility and risk, GRTX or SCYX?

Does the media favor GRTX or SCYX?

Do institutionals and insiders hold more shares of GRTX or SCYX?

Do analysts rate GRTX or SCYX?

Which has stronger earnings & valuation, GRTX or SCYX?

Summary

How does Galera Therapeutics compare to Mainz Biomed?

Do analysts recommend GRTX or MYNZ?

Which has more risk and volatility, GRTX or MYNZ?

Which has higher earnings & valuation, GRTX or MYNZ?

Is GRTX or MYNZ more profitable?

Do insiders and institutionals hold more shares of GRTX or MYNZ?

Does the media refer more to GRTX or MYNZ?

Summary

How does Galera Therapeutics compare to Lisata Therapeutics?

Do institutionals & insiders believe in GRTX or LSTA?

Is GRTX or LSTA more profitable?

Does the media refer more to GRTX or LSTA?

Which has preferable earnings & valuation, GRTX or LSTA?

Do analysts prefer GRTX or LSTA?

Which has more volatility & risk, GRTX or LSTA?

Summary

How does Galera Therapeutics compare to Quantum Biopharma?

Do institutionals & insiders hold more shares of QNTM or GRTX?

Is QNTM or GRTX more profitable?

Does the media favor QNTM or GRTX?

Which has higher earnings and valuation, QNTM or GRTX?

Do analysts rate QNTM or GRTX?

Which has more risk & volatility, QNTM or GRTX?

Summary

How does Galera Therapeutics compare to BGM Group?

Do analysts recommend BGM or GRTX?

Is BGM or GRTX more profitable?

Does the media prefer BGM or GRTX?

Do insiders and institutionals believe in BGM or GRTX?

Which has higher valuation & earnings, BGM or GRTX?

Which has more risk and volatility, BGM or GRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRTX vs. The Competition

Galera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools